

# LONG-TERM STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY CETUXIMAB

Inmaculada SUÁREZ GONZÁLEZ<sup>1</sup>, Natalia NAVAS IGLESIAS<sup>2</sup>, Antonio MARTÍNEZ ORTEGA<sup>1</sup>,

Jose HERNÁNDEZ JIMÉNEZ<sup>1</sup>, Antonio SALMERÓN GARCÍA<sup>3</sup>, José CABEZA BARRERA<sup>3</sup>

(1) Department of Analytical Chemistry, Faculty of Science, University of Granada, Avda. Fuentenueva s/n, Gr-18071 Spain.


(2) Department of Analytical Chemistry- Science Faculty, Biomedical Research Institute ibs.GRANADA, University of Granada, Avda. Fuentenueva s/n, Gr-18071 Spain.

(3) Hospital Pharmacy Unit, Complejo Hospitalario Universitario de Granada, Biomedical Research Institute ibs.GRANADA, E-18012 Granada.

**Objective:** To assess the long term stability of the therapeutic monoclonal antibody **Cetuximab (Erbix®)** once the single-dose vial was open (5.0 mg/ml) and diluted with 0.9 % NaCl to a final concentration of 2.0 mg/ml. The solutions were stored in dark glass vials refrigerated at 4 ° C and frozen at -20 ° C.

## Background:


**Cetuximab (CTX)** (Erbix®) is a chimeric mouse-human monoclonal antibody IgG1 targeting **epidermal growth factor receptor (EGFR)**. It is approved for use as treatment for metastatic colorectal cancer and squamous cell carcinoma of the head and neck.



From: [http://www.rxiist.com/gkggeneric/erbitux\\_ids.htm](http://www.rxiist.com/gkggeneric/erbitux_ids.htm)

## Materials and methods:

Ad hoc methods for assessing the **physicochemical properties** of cetuximab were developed and ICH validated: reverse phase high performance liquid chromatography with diode array detector [(RP)HPLC-DAD] for **quantification**; weak cation exchange high performance liquid chromatography [(WCE)HPLC-DAD] to track changes in the **isoforms profile**; size exclusion chromatography high performance liquid chromatography with diode array detector [(SEC)HPLC-DAD] for **aggregates** detection; and electrospray quadrupole/time of flight mass spectrometry (ESI-qTOF-MS) to obtain molecular weight in order to detect **changes in the chemical structure**. **Biological activity** was assessed using a specific immunoassay based on the **ELISA** technique using plates sensitized with the **Epidermal Growth Factor Receptor (EGFR)**.



## Results:

The decrease of biological activity was only 5 % after 24 hours the vial was open (5 mg/ml), raising 14% at day 3, 20% after a week, with a final decrease of 85% for the last control day (30 days). The overall quantity of CTX was unchanged for the month assessed. No aggregates formation was detected in the two weeks tested. Changes in the chromatographic isoforms profile (2 mg/ml) were detected after a week, with important isoforms variations from week 2 up to the end of the study (two months). Molecular weight indicated not major changes in the CTX structure (one month).

## Conclusion:

Both the physicochemical and the biological properties assessed indicated good stability of the CTX within 24 hours after the vial was open. Even there was not an important decrease of the biological activity after a week of the opening of the medicine (20% decreased) with unchanged physicochemical properties for six days.  
**Authors declare no conflict of interest**

## Acknowledgements:

This work was entirely funded by Project FIS:PI10/00201 (Instituto Carlos III, Ministerio de Economía y Competitividad, Government of Spain). The authors would like to thank the Hospital Pharmacy Unit of the University Hospital of "San Cecilio" for kindly supplying all the medicine samples and the Biomedical Research Foundation "Alejandro Otero" (FIBAO) for the support given during the course of this research.